EXSCIENTIA-LTD.
13.5.2021 09:32:13 CEST | Business Wire | Press release
Exscientia Ltd. (Headquarters: Oxford, UK; CEO: Andrew Hopkins) is pleased to acknowledge that Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka, Japan, Representative Director, President and CEO: Hiroshi Nomura) has announced that they will initiate a Phase 1 clinical study of DSP-0038 in the United States for the treatment of Alzheimer’s disease psychosis.
DSP-0038 is the third molecule created using Exscientia’s Artificial Intelligence (AI) technologies to enter clinical trials. The two earlier compounds are DSP-1181, announced in 2020 together with Sumitomo Dainippon Pharma to treat obsessive-compulsive disorder, and Exscientia’s immuno-oncology agent, EXS-21546, announced earlier this year.
Joint research between Exscientia and Sumitomo Dainippon Pharma designed DSP-0038 to be a single small molecule that exhibits high potency as an antagonist for the 5-HT2A receptor and agonist for the 5-HT1A receptor, whilst selectively avoiding similar receptors and unwanted targets, such as the dopamine D2 receptor. Selective dual targeting is a major challenge for conventional drug discovery, and psychiatric indications also require exceptional selectivity to avoid off-target effects. The successful design of DSP-0038 demonstrates opportunities to design selective molecules with dual activity.
DSP-0038 will be assessed for improved antipsychotic effects associated with Alzheimer’s disease psychosis, as well as improvements in behavioural and psychological symptoms of dementia which include agitation, aggression, anxiety, and depression.
Toru Kimura, Representative Director, Executive Vice President and Chief Scientific Officer of Sumitomo Dainippon Pharma, said: "We have been impressed by the outstanding productivity of Exscientia's AI technologies. The combination of Exscientia’s AI with our company’s deep experience in monoamine GPCR drug discovery has now led to two molecules reaching our clinical pipeline from this collaboration.”
Andrew Hopkins, CEO of Exscientia, said: "This is further validation that our AI platform can turn complex biological challenges into high-quality clinical candidates quickly. To have what we believe to be the world’s first three clinical molecules created using AI arising from our own platform – two with Sumitomo Dainippon Pharma - is a wonderful achievement. We hope that through the creation of DSP-0038 improved treatments for Alzheimer’s disease psychosis will be realized."
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering and designing the best possible medicines in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drugs are created. Exscientia’s AI platform has now designed two drugs that are in Phase 1 human clinical trials.
Drug design is precision engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of design. Because Exscientia’s AI platform learns more effectively and rapidly than human-led efforts alone, candidate molecules satisfying complex therapeutic requirements are created with revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best ideas of science to rapidly become the best medicines for patients.
Exscientia has offices in Oxford, Miami, Osaka and Dundee. For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI.
About Sumitomo Dainippon Pharma Co., Ltd.
Sumitomo Dainippon Pharma defines its corporate mission as "To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide." By pouring all our efforts into the research and development of new drugs, we aim to realize our corporate mission and provide innovative and effective pharmaceutical
solutions to people not only in Japan but also around the world. Sumitomo Dainippon Pharma's goal is to create innovative pharmaceutical products in the focus research areas of Psychiatry & Neurology, Oncology and Regenerative Medicine/Cell Therapy. For further details, visit https://www.ds-pharma.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005059/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mindbreeze InSpire Reduces Token Maxxing, Turning Runaway AI Costs Into Predictable Enterprise Value28.7.2026 15:03:00 CEST | Press release
By grounding generative AI in precise, governed enterprise knowledge, Mindbreeze InSpire cuts the wasted tokens that inflate AI budgets and erode answer quality. Mindbreeze, a leading global provider of AI-based knowledge management solutions, today announced that Mindbreeze InSpire reduces token maxxing, the costly overconsumption of large language model (LLM) tokens that is straining enterprise AI budgets. By retrieving only the most relevant, grounded content and passing it to LLMs with precision, Mindbreeze InSpire lowers the tokens required per answer while improving accuracy, giving enterprises a path to scalable AI with predictable economics. Token maxxing has become one of the most underestimated risks in enterprise AI. As organizations connect generative AI to their data, many default to injecting large volumes of undifferentiated context into every prompt, repeatedly, across thousands of queries. Industry analysis has warned that tokens are becoming the true unit of AI cost,
Uptime Institute 16th Annual 2026 Global Data Center Survey: Deployment of High Density Racks Rising Fast, Operators Face Continued Recruiting and Retention Pressures28.7.2026 15:02:00 CEST | Press release
Uptime Institute today released the findings of its 16th Annual Global Data Center Survey, the most comprehensive study of the digital infrastructure sector. The 2026 results reveal an industry navigating workforce constraints, escalating outage expenses, even as rising costs remain the top concern for management teams. Financial Pressure and Resource Constraints Intensify: While high costs continue to be a primary concern for data center leaders, the 2026 survey also highlights escalating concerns over capacity forecasting, power availability, and supply chain disruptions. Power efficiency gains remain gradual. The industry saw minor improvements in average Power Usage Effectiveness (PUE) levels this year. While newer facilities may boast highly efficient designs, overall global progress is slowed by legacy infrastructure. The AI and Density Reality Check: Despite market enthusiasm for Artificial Intelligence, expectations for AI in data center operations cooled slightly in 2026. Oper
Torq Unveils the SOC Brain: The AI SOC That Learns, Not Just Remembers28.7.2026 15:00:00 CEST | Press release
New Torq AI SOC Platform layer’s innovative capabilities learn from every security decision and historical incident, drawing conclusions from precedents and team judgments from day zero Torq, the established agentic security operations leader, today introduced Torq SOC Brain™, a new layer of the Torq AI SOC Platform that continuously learns from historical investigations, analyst decisions, and organization-specific security operations to create a unified, self-learning AI SOC. While most autonomous investigation systems claim to be self-learning, they are, in reality, memory systems—they simply retrieve past cases and pass them to a language model at decision time. Torq SOC Brain is fundamentally different. It reasons from precedent, adapts to how each SOC evaluates risk, and continuously refines its judgment with every completed investigation. The result is an AI SOC that grows more accurate over time—not a thin wrapper around a generic AI model. This press release features multimedi
AUTOBACS SEVEN Marks 10 Years of System Stability and Self-Funded Innovation with Rimini Street28.7.2026 15:00:00 CEST | Press release
Japan’s leading automotive aftermarket retailer uses Rimini Smart Path™ to accelerate innovation without disrupting its core SAP ECC and Oracle Database systems Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that AUTOBACS SEVEN Co., Ltd. celebrates its 10-year partnership with Rimini Street, marking a decade of stable core operations and reinvestment in innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728266493/en/ AUTOBACS SEVEN Marks 10 Years of System Stability and Self-Funded Innovation with Rimini Street Since switching to Rimini Support™ for SAP ECC 6 in 2016, AUTOBACS SEVEN has expanded its partnership to include Oracle Database, helping the company stabilize mission-critical systems, reduce maintenance burden and free resources for innovation. “At AUTOBACS SEVEN, our lea
Abnormal AI Extends its Behavioral Security Platform to Identity and AI Security28.7.2026 15:00:00 CEST | Press release
Abnormal launches three new products: Identity Threat Protection, AI Governance, and Infiltration Prevention to secure the modern identity attack surface Abnormal AI, the AI-native behavior security company trusted by more than 25% of the Fortune 5001, today announced the expansion of its Behavioral Security Platform across the enterprise, introducing three new products: Identity Threat Protection, AI Governance, and Infiltration Prevention. Together, the launch extends the behavioral AI that already secures over 4,500 customers1 to the identities, AI systems and onboarding pipeline that attackers increasingly exploit. Additionally, customers can now activate products from the AI App Store, a new interface to turn on Abnormal products in a single click. For nearly a decade, Abnormal has protected organizations by understanding behavior, learning what normal looks like for every identity and detecting the deviations that signal anomalous activity or an attack. That behavioral foundation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom